164 related articles for article (PubMed ID: 38135836)
21. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
22. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.
Guarini C; Grassi T; Pezzicoli G; Porta C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202896
[TBL] [Abstract][Full Text] [Related]
23. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
[TBL] [Abstract][Full Text] [Related]
24. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
[TBL] [Abstract][Full Text] [Related]
25. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
[TBL] [Abstract][Full Text] [Related]
26. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
27. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
28. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
29. Human epidermal growth factor receptor 2-positive digestive tumors.
Wagner AD; Özdemir BC; Rüschoff J
Curr Opin Oncol; 2019 Jul; 31(4):354-361. PubMed ID: 31170116
[TBL] [Abstract][Full Text] [Related]
30. Personalized therapeutic strategies in HER2-driven gastric cancer.
Ughetto S; Migliore C; Pietrantonio F; Apicella M; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Rizzolio S; Capelôa T; Ribisi S; Degiuli M; Reddavid R; Rapa I; Fumagalli U; De Pascale S; Ribero D; Baronchelli C; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Manenti S; Bencivenga M; Sacco M; Castelli C; Siena S; Sartore-Bianchi A; Tosi F; Morano F; Raimondi A; Prisciandaro M; Gloghini A; Marsoni S; Sottile A; Sarotto I; Sapino A; Marchiò C; Cassoni P; Guarrera S; Corso S; Giordano S
Gastric Cancer; 2021 Jul; 24(4):897-912. PubMed ID: 33755862
[TBL] [Abstract][Full Text] [Related]
31. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
33. Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer.
Lazure P; Marshall JL; Hayes SM; Murray S
Clin Colorectal Cancer; 2016 Mar; 15(1):54-66. PubMed ID: 26341411
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
35. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
36. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A; Atreya C; Korn WM; Venook AP
J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.
Chen Z; Chen J; Gao Y; Quan M
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1097-1104. PubMed ID: 34130577
[No Abstract] [Full Text] [Related]
38. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
Takegawa N; Yonesaka K
Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
